Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq: SCMP) announced an option and collaboration agreement under which Cancer Prevention Pharmaceuticals, Inc. (CPP) has granted Sucampo the sole option to acquire an exclusive license to commercialize CPP-1X/sulindac combination product in North America. This product is currently in a Phase 3 clinical trial for the treatment of familial adenomatous polyposis (FAP).
{iframe}http://www.streetinsider.com/Corporate+News/Sucampo+Pharma+(SCMP)+Enters+Option+Agreement+to+License+CPP-1XSulindac+Product+in+North+America/11207566.html{/iframe}